Un des enjeux en génie microbien est de produire des quantités élevées de protéines. Parmi les hôtes disponibles pour la production hétérologue de protéines, Lactococcus lactis est une bactérie à fort potentiel. Son innocuité et son caractère gram positif en fait un hôte de choix pour la production de protéines d'intérêt. Parmi ces protéines figurent des bactériocines, qui sont des proteines antibactériennes pouvant être utilisées à des fins de sécurité sanitaires des aliments voire comme antibiotique. Ces travaux ont pour ambition d'améliorer la production hétérologue de la bactériocine pédiocine chez L. lactis au niveau quantitatif et qualitatif en ciblant respectivement les étapes de sécrétion et de maturation post-traductionnelle. La sécrétion a été améliorée en insérant les pro-peptides SD ou LEISSTCDA entre le peptide signal de sécrétion et la séquence de la bactériocine. Il a été montré que cette insertions n’affectent pas l’activité antibactérienne. L’analyse in silico de l’opéron responsable de la production de pédiocine chez la bactérie productrice sauvage a révélé que le gène pedC code une protéine prédite comme thiol-disulfide oxydoréductase, suggérant un rôle de cette protéine dans le statut redox des cystéines de la pédiocine. La co-expression de PedC avec la pédiocine recombinante a permis d’augmenter son pouvoir antibactérien. Les résultats obtenus pendant cette thèse ont ainsi montré que la production de pédiocine par L. lactis peut être améliorée par fonctionnalisation de l’extrémité N-terminale sans effet significatif sur le potentiel antibactérien et que PedC joue un rôle majeur dans le potentiel antibactérien de la pédiocine / Lactococcus lactis is considered an efficient cell factory for recombinant protein production. It is able to produce and secrete class IIa bacteriocins such as pediocin PA-1 via the general secretion (Sec) pathway. However, the positive charges at the N-terminus of pediocin PA-1 might impair secretion via the Sec secretion pathway and the obtained recombinant pediocin has been described as less potent than the pediocin from the natural producer. The impact of two propeptides on the production yield and on the potency of recombinant pediocins was investigated. The nucleotide sequences encoding the propeptides SD or LEISSTCDA were inserted between the sequence encoding the signal peptide of Usp45 and the structural gene of the mature pediocin PA-1. Both propeptides improved secretion of the recombinant pediocins. Although no major impact on the antibacterial activity of recombinant pediocins was observed, all recombinant bacteriocins produced in L. lactis were less potent than wildtype pediocin. Co-expression of the putative thiol-disulfide oxidoreductase PedC, which is encoded by the pediocin PA-1 operon, with the recombinant pediocins allowed to significantly decrease the minimal inhibitory concentration of the produced bacteriocins. To our knowledge, this report shows for the first time that the propeptides SD or LEISSTCDA lead to an improved secretion of recombinant pediocins with apparently no effect on the antibacterial potency and that PedC plays a major role in the potency of pediocin

Il est reconnu, depuis des années, que la flore intestinale par son équilibre complexe et dynamique joue un rôle essentiel dans la santé humaine. Une des stratégies les plus prometteuses pour la maintenir ou l’améliorer consiste à moduler le microbiome par l’utilisation de bactéries probiotiques ou de sucres prébiotiques. C’est dans ce contexte que s’inscrivent les études structurales et fonctionnelles d’α glucosidases bactériennes développées dans cette thèse. Ces enzymes hydrolysant les liaisons α-(1,4) glucosidiques sont classées, selon la base de données CAZy, dans les familles de glycoside hydrolases (GH) 4, 13, 31, 63, 97 et 122. Ces travaux de thèse, centrés sur trois α-glucosidases issues de Lactobacillus bulgaricus (11842aglu, GH31), Lactococcus lactis (1403aglu, GH13) et Shewanella sp. ANA-3 (SHWaglu, GH97), exposent la mise au point de leurs protocoles de surexpression et de purification. Ils présentent également des études bioinformatiques de 11842aglu et de 1403aglu, ainsi qu’une caractérisation enzymatique préliminaire de cette dernière. Une analyse structurale et fonctionnelle approfondie de SHWaglu a aussi été réalisée. La résolution, par cristallographie aux rayons X, des structures de SHWaglu seule, en complexe avec différents ligands et de mutants, a participé à enrichir les connaissances, jusqu’à présent peu étendues, sur les enzymes de la famille GH97. Ainsi, un motif structural conservé au sein de cette famille a notamment été mis en évidence. Par ailleurs, ces informations structurales combinées aux études enzymatiques ont permis de révéler des déterminants moléculaires de l’activité de cette α-glucosidase et, par conséquent, d’établir les relations structure-fonction-activité de cette enzyme. Ainsi, l’ensemble des données obtenues, couplé à des études d’ingénierie protéique, contribue à ouvrir de nouvelles perspectives industrielles, notamment en suggérant d’optimiser ou de conférer des activités enzymatiques modifiées dans certaines cibles de choix afin de leur faire synthétiser des sucres de type prébiotiques / It is now generally accepted that the gut flora with its complex and dynamic nature plays a vital role in human health. One of the most promising strategies for maintaining or improving health is to modulate the microbiome by the use of probiotics and prebiotics as food supplements. The structure/function/activity relationship studies of bacterial α-glucosidases described in this thesis have been performed within this context. These α-(1,4)-glucosidic bond hydrolyzing enzymes are classified, according to the CAZy database, into glycoside hydrolases families (GH) 4, 13, 31, 63, 97 and 122. This thesis work, has focused on three α-glucosidases from Lactobacillus bulgaricus (11842aglu, GH31), Lactococcus lactis (1403aglu, GH13) and Shewanella sp. ANA-3 (SHWaglu, GH97), and the development of their overexpression and purification protocols. It also presents a bioinformatics studies of 11842aglu and 1403aglu, as well as preliminary enzymatic characterization of the latter. As for SHWaglu, detailed structural and functional studies have been carried out. The crystal structures of SHWaglu in its native state, in complex with different ligands as well as site directed mutants have contributed to increase our knowledge on enzymes from the GH97 family which to date remains relatively limited. Notably, a conserved structural motif in this family has been identified. Overall, the structural- and enzymatic studies and analyses have revealed molecular-and structural determinants governing the activity and broad substrate specificity of this α-glucosidase which is adapted to cold temperatures. Apart from the insight gained from a fundamental research point of view, data described within this work, coupled with protein engineering studies may contribute to open up new industrial perspectives, in particular by suggesting optimized or altered enzyme activities in some attractive enzyme targets with the aim of synthesizing prebiotic compounds

Após a constatação da escassez de estudos realizados com vegetais crus na busca por novas estirpes de bactérias láticas (BAL) produtoras de bacteriocinas e diante do potencial tecnológico da aplicação destas cepas tanto como agentes de conservação em alimento, bem como cultura probiótica em alimentos funcionais, este estudo objetivou isolar e identificar cepas de bactérias láticas potencialmente bacteriocinogênicas de amostras de rúcula obtidas no comércio local de São Paulo, SP - Brasil, identificar e caracterizar as bacteriocinas produzidas pelos isolados e avaliar o potencial probiótico dos isolados testando sua sobrevivência no modelo dinâmico do trato gastrointestinal TNO gastro-Intestinal Model - TIM-1 disponível no TNO (The Netherlands Organization for Applied Scientific Research) divisão Quality of Life (Zeist, Holanda). A produção de bacteriocinas neste modelo também foi avaliada, comparando-se com L. sakei 2a, também produtora de bacteriocinas e ainda avaliou-se a interferência na viabilidade de E. faecium LMA1. A cepa Lactococcus lactis subsp. lactis MK02R de rúcula produziu uma bacteriocina sensível à enzimas proteolíticas, termoestável e não influenciada pelo pH, sendo capaz de inibir Enterococcus faecium, Lactobacillus sakei, Listeria innocua, Lactobacillus delbrueckii e Listeria Monocytogenes de diferentes grupos sorológicos. Os ensaios genéticos utilizando primers Nisf e Nisr confirmaram que a bacteriocina MK02R é uma nisina, apresentando uma alteração dos aminoácidos no peptídeo líder em relação às nisinas A, Z, Q, F e U, porém com a estrutura do peptídeo maduro idêntica ao da nisina F. Estes resultados foram confirmados por espectrometria de massas de amostras purificadas por HPLC. L. lactis MK02R resistiu à passagem no modelo dinâmico TIM-1, apresentando uma alta capacidade de sobreviver nas condições simuladas do trato gastrointestinal humano. Entretanto, não foi capaz de causar a redução no número de E. faecium LMA1. Em contrapartida, L. sakei 2a, mesmo apresentando uma sobrevivência menor, foi capaz de causar uma redução de 70% na população de E. faecium LMA1 no ambiente simulado do TGI. Não foi detectada atividade residual da ação antimicrobiana das bacteriocinas produzidas por L. lactis MK02R ou L. sakei 2a após a passagem pelo modelo dinâmico TIM-1. Estes resultados evidenciam a possível aplicação de L. lactis MK02R como um agente de controle biológico na conservação de alimentos e também como uma cultura potencialmente probiótica. / Given the scarcity of studies performed with raw vegetables addressing the search for new bacteriocinogenic strains of lactic acid bacteria (LAB) and considering the technological application of these strains as food preservatives and probiotic cultures in functional foods, this study was aimed at isolation and identification of bacteriocinogenic LAB strains from samples of rocket salad obtained in the local market of São Paulo, SP - Brazil, subsequent characterization of the bacteriocins produced by these LABs and evaluation of their probiotic potential by testing their survival in the dynamic gastrointestinal model TNO gastro- Intestinal-Model - TIM-1, available at the TNO (Netherlands Organization for Applied Scientific Research) Quality of Life division (Zeist, Netherlands). The studies in the TIM-1 model were also done with another bacteriocinogenic strain L. sakei 2a for comparison, evaluating their interference on the viability of E. faecium LMA1. The bacteriocin produced by strain Lactococcus lactis subsp. lactis MK02R isolated from rocket salad was sensitive to proteolytic enzymes, heat-stable and not influenced by the pH. The bacteriocin inhibited the growth of Enterococcus faecium, Lactobacillus sakei, Listeria innocua, Lactobacillus delbrueckii the primers Nisf and Nisr indicated that the bacteriocin produced by the strain MK02R is a nisin, with a change in the amino acid sequence of the leader peptide when compared to nisin A, Z, Q, U and F, but with the structure of the mature peptide homologous to that of nisin F. These results were confirmed by mass spectrometry of purified samples obtained by HPLC. L. lactis MK02R withstood the test in the dynamic model TIM-1, presenting capability to survive in the simulated conditions of the human gastrointestinal tract. However, the strain was not able to cause a reduction in the number of E. faecium LMA1. On the other hand, L. sakei 2a, even presenting lower survival, was able to cause 70% reduction in the population of E. faecium LMA1 in the gut simulated environment. No residual antimicrobial activity of bacteriocin produced by L. lactis MK02R or L. sakei 2a was detected after the transit through the dynamic model TIM-1. These results demonstrate the possible application of L. lactis MK02R both as a biocontrol agent in food preservation and as a potentially probiotic culture.

Les maladies inflammatoires chroniques de l’intestin (MICI) regroupent la colite ulcéreuse (CU) et la maladie de Crohn (MD) qui sont des troubles intestinaux caractérisés par une inflammation chronique du tractus gastro-intestinal. Les MICI sont provoquées par un dysfonctionnement du système immunitaire de la muqueuse vers le microbiote intestinal chez les individus génétiquement prédisposés, menant à des réponses immunitaires pro-inflammatoires excessives. L'incidence de ces maladies augmente dans les pays développés et sont devenues de grands problèmes gastroentérologiques, surtout que les médicaments de traitement actuels sont associés à de graves effets collatéraux. Ainsi, les dernières recherches se concentrent sur le développement de nouvelles stratégies pour le traitement des MICI. Les probiotiques, en particulier celles qui appartiennent au groupe des bactéries lactiques (BL), se montrent capables de prévenir et de traiter les MICI en rétablissant l'équilibre du microbiote perturbé et en supprimant les réponses immunitaires pro-inflammatoires. Afin d'augmenter l’effet probiotique des BL, le clonage moléculaire et l'expression des molécules anti-inflammatoires ont été réalisés et les souches recombinantes des BL ont été évaluées comme un traitement alternatif pour les MICI. L'utilisation de ces souches, en particulier le modèle Lactococcus lactis, a montré son efficacité dans la lutte contre l'inflammation intestinale. Son administration comme thérapie pour traiter d'autres maladies inflammatoires du tractus gastro-intestinal, tels que la mucite, a également été évaluée. La mucite est un effet secondaire fréquent chez les patients subissant une radiothérapie ou une chimiothérapie qui affecte fortement leur qualité de vie. Comme pour les MICI, le traitement de la mucite est assez limité, seuls quelques médicaments et procédures décrits peuvent en effet contenir les ulcérations et l'inflammation. Par conséquent, ilest nécessaire de développer des traitementsalternatifs pour les MICI et la mucite. Le but de cette étude est de tester l'efficacité de la souche de L. lactis recombinante exprimant la protéine associée à la pancréatite I (PAP) afin de lutter contre les MICI et la mucite dans des modèles de souris. La PAP a été rapportée comme une protéine ayant des propriétés antimicrobiennes qui jouent un rôle important pour maintenir l'homéostasie intestinale. Tout d'abord, nous avons construit et confirmé l'expression de la PAP humaine par recombinant L. lactis. Ensuite, nous avons évalué l'effet thérapeutique de cette souche dans un modèle de souris de Dinitrobenzene acide sulfonique (DNBS) afin d’induire la colite. En outre, la livraison de PAP par lactocoques a protégé les animaux d’une perte de poids, de la perméabilité intestinale, et de lésions tissulaires. De plus, le traitement L. Lactis-PAP a diminué Th1 (IFN-y), Th2 (IL-4, IL-5) et Th17 (IL-17) de type-réponses immunitaires. On a également observé une expression élevée de régulation de cytokines TGF-β ainsi qu’une augmentation de la quantité de cellules T régulatrices chez les souris traitées. Les effets anti-inflammatoires des L. Lactis-PAP et des souches des produits laitiers L. lactis NZ9000 ont également été mesurés dans le modèle d'inflammation des muqueuses 5-Fluorouracil (5-FU). L'administration de L. lactis NZ9000 hébergeant le vecteur pSEC sans l'ADNc de PAP a été en mesure de prévenir les dommages histologiques, de réduire l’infiltration des éosinophiles et de la sécrétion d'IgA dans l'iléon de souris. D'autre part, L. lactis exprimant la PAP a conservé l'architecture muqueuse et a amélioré l'activité des cellules de Paneth. En même temps, nos résultats démontrent que L. lactis, exprimant PAP est une stratégie prometteuse pour traiter les MICI. En outre, la souche L. lactis NZ9000 de manière surprenante, a présenté des effets anti-inflammatoires chez les souris injectées avec du 5-FU. / Inflammatory Bowel Diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD) are complex intestinal disorders characterized by chronic inflammation of the gastrointestinal tract (GIT). IBD are caused by a deregulation of the mucosal immune system toward the native intestinal microbiota in genetically predisposed individuals, leading to excessive pro-inflammatory immune responses in the GIT. The incidence of both diseases is increasing in developed countries turning CD and UC a main gastroenterological problem as current treatment drugs are associated with serious side effects. Thus, recent research is focusing on the development of new strategies for the treatment of IBD. Probiotic bacteria especially the ones belonging to the lactic acid bacteria (LAB) group, were shown to be capable of preventing and treating IBD by restoring the balance of disrupted microbiota and suppressing pro-inflammatory immune responses. In order to increase LAB probiotic effect, molecular cloning and expression of anti-inflammatory molecules are being carried out and LAB recombinant strains are also being evaluated as an alternative treatment for IBD. As the use of these strains, especially the model Lactococcus lactis, showed to be very effective in fighting intestinal inflammation, its administration as a therapy for treating other human GIT inflammatory diseases, such as mucositis, are also being evaluated. This disorder is a common side effect of patients undergoing radiotherapy or chemotherapy that strongly affects their quality of life. Like IBD, treatment for mucositis is very limited with few medicaments and procedures described to contain inflammation. Therefore, given the need to develop alternative treatments for both IBD and mucositis, this study aimed to test theefficacy of either dairy L. lactis NZ9000 or recombinant L. lactis strain expressing Pancreatitis Associated Protein I (PAP) to fight inflammation in mouse models of IBD and mucositis. PAP has been reported as a protein with antimicrobial properties that plays important roles to keep intestinal homeostasis. Firstly, we constructed and confirmed the expression of human PAP by recombinant L. Lactis. Afterwards, we evaluated the therapeutic effect of this strain in a mice model of dinitrobenzenosulfonic acid (DNBS)-induced colitis. Moreover, PAP delivery by lactococci protected animals from weight loss, intestinal permeability, and tissue damage. In addition, L. lactis-PAP treatment decreased Th1 (IFNγ), Th2 (IL-4, IL-5) and Th17 (IL-17) type-immune responses. It was also observed a higher expression of regulatory TGF-β cytokine and increased amount of T regulatory cells in treated mice. The anti-inflammatory effects of both L. lactis-PAP and dairy L. lactis NZ9000 strains were also measured in 5-fluoracil mucositis model. We showed that this model was successfully reproduced in BALB/c mice with an induction of acute inflammation in the small bowel of animals. Administration of L. lactis NZ9000 harboring pSEC vector without the cDNA of PAP was able to prevent histological damage, reduce eosinophils infiltrate and IgA secretion in the ileum of mice. On the other hand, L. lactis expressing PAP preserved mucosal architecture and improved Paneth cells activity. Taking together, our results demonstrate that L. lactis, expressing PAP peptide is a promising strategy to treat IBD. Moreover, L. lactis NZ9000 strain, derived from dairy L. lactis MG1363, surprisingly presented anti-inflammatory effects in mice injected with 5-FU.

Thesis (MSc)--Stellenbosch University, 2011. / ENGLISH ABSTRACT: The interests in understanding the metabolic processes of microbial systems are numerous. The interest in the species Lactococcus lactis (L. lactis) lies in applications to the food industry and in studies comparing the metabolism of related organisms. The aim of this study was to perform in vivo supply-demand analysis on anaerobically fermenting L. lactis. This was done by perturbing both the supply and demand pathways, then measuring glycolytic flux (by means of 13C NMR spectroscopy) and intracellular ATP/ADP (by means of 31P NMR spectroscopy) at steady state – where the central metabolite, ATP, is produced at the same rate as it is consumed and its concentration thereby remains constant. The L. lactis reference strain MG1363 was supplemented with glucose and analysed “online” by 13C-NMR under anaerobically-fermentative conditions. The rates of glucose consumption and lactate production were determined from this 13C flux. Due to experimental difficulties with the online detection of 31P (possibly due to the low biomass yield and the choice of growth medium), ATP/ADP levels had to be determined offline: from the same batch cultures as the 13C samples, fermentations were performed and halted at time points when the cells had attained a steady state. These fermentation cultures were then subjected to cell lysis and centrifugation in order to extract intracellular metabolites. These cell extracts were analysed offline by 31P NMR in order to determined levels of phosphate metabolites, specifically ATP and ADP. Perturbation of the supply pathway was achieved by utilising a genetically modified strain (the CS8 strain with over-expressed las operon) and comparing it to the reference strain MG1363. This resulted in a slight increase in ATP/ADP, but also yielded a slightly reduced flux, which is contrary to expectations from a mutant with over expressed glycolytic enzymes. The demand pathway was perturbed by two methods: 1) utilisating a genetically modified strain (the BK1506 strain with over-expressed F1-ATPase) and comparing it to the reference strain MG1363, and 2) by treating wild-type MG1363 with sodium acetate and comparing flux and ATP/ADP values to the untreated wild-type. Sodium acetate dissociates in the cytoplasm and causes dissipation of the transmembrane proton motive force, which is re-established by upregulation of membrane-bound H+-translocating ATPases. While the use of genetically modified strains provided only one flux-vs-ATP/ADP data point to compare to the wild-type (not sufficient for complete supply-demand analysis), the treatment of the wild type with uncoupler yielded several data points where flux and ATP/ADP values differed according to the concentration of uncoupler added. The CS8 strain demonstrated a 19 % reduced glucose flux (24 % reduced lactate flux) with respect to the wild type MG1363. The BK1506 strain demonstrated a 72 % increase in glucose flux (33 % increase in lactate flux) with respect to the wild type. The treatment with 2 mM acetate resulted in a 72 % increase in glucose flux (123 % increase in lactate flux), whereas treatment with 4 mM acetate resulted in a 107 % and a 126 % increase in glucose and lactate fluxes, respectively. The treatment with different concentrations of acetate provided several data points with corresponding flux and ATP/ADP, enabling the calculation of the elasticity coefficient of the supply pathway to changes in ATP/ADP (εsupply ) which was found to be -5.6 and -6.3 for glucose and lactate, respectively. ATP/ADP The elasticity coefficient was high compared with values obtained in similar studies on other organisms. Considering that at steady state the supply and demand fluxes are equal, the high supply elasticity (which is easier to measure), when incorporated into control coefficient summation theorems, gives the indication that: 1) a greater amount of control may reside in the ATP demand pathway (the elasticity of which is more difficult to determine experimentally, but which may well be lower than the supply elasticity), and 2) ATP/ADP homeostasis is good, as indicated by a high elasticity of the supply pathway to ATP/ADP. This study represents a basis for further supply-demand analysis with non-growing batch cultures of L. lactis. / AFRIKAANSE OPSOMMING: Daar is groot belangstelling daarin om die metaboliese prosesse van mikrobiese sisteme beter te verstaan. Die belang van die spesie Lactococcus lactis (L. lactis) lê beide in die toepassing in die voedselbedryf en in studies wat die metabolisme van verskeie organismes vergelyk. Die doel van hierdie studie was om in vivo vraag-aanbod analise uit te voer op anaerobies-fermenterende L. lactis. Dit was gedoen deur beide die aanbod en vraag reaksie-blokke te moduleer en dan die glikolitiese fluksie (d.m.v. 13C KMR spektroskopie) en die intrasellulêre ATP/ADP (d.m.v. 31P KMR spektroskopie) in ’n bestendige toestand te meet (wanneer die sentrale metaboliet, ATP, teen dieselfde tempo geproduseer en verbruik word en sy konsentrasie daardeur konstant bly). Die L. lactis verwysing-stam MG1363 is met glukose aangevul en 13C fluksie is aanlyn onder anaerobies-fermenterende kondisies gemeet. Die tempo van glukose verbruik en laktaat produksie is vanaf die 13C fluksie bereken. Eksperimentele probleme met die aanlyn bepaling van 31P (dalk as gevolg van lae biomassa en/of die keuse van groeimedium) moes ATP/ADP vlakke af-lyn indirek bepaal word: fermentasies van dieselfde lot-kulture as die 13C monsters is opgestel en by sekere tydpunte gestop wanneer ‘n bestendige toestand bereik was (waar ATP/ADP konstant bly). Hierdie fermenterende kulture is blootgestel aan sel-lise en sentrifugasie om intrasellulêre metaboliete te onttrek. Dié sel-ekstrakte is deur 31P KMR geanaliseer om die vlakke van fosfaat metaboliete, spesifiek ATP en ADP, te bepaal. Die aanbod blok is gemoduleer deur gebruik te maak van ‘n geneties-gemodifiseerde stam (die CS8 stam met ‘n ooruitgedrukte las operon) en met die verwysing stam MG1363 te vergelyk. Dié gemuteerde stam het ’n effense toename in ATP/ADP getoon, maar het gelyktydig ook ’n afname in glikolitiese fluksie getoon, wat onverwags is vir ’n stam met ooruitgedrukte glikolitiese ensieme. Die vraag blok is met twee metodes gemoduleer: 1) deur gebruik te maak van ‘n geneties-gemodifiseerde stam (die BK1506 stam met ‘n ooruitgedrukte F1-ATPase), en 2) deur die wildetipe MG1363 met natrium asetaat te behandel en daardeur ATP verbruik van biomassa produksie te ontkoppel en die vraag na ATP te vermeerder. Daarna word die fluksie en ATP/ADP waardes met die onbehandelde wildetipe vergelyk. Natrium asetaat dissosieer in die sitoplasma en verswak die transmembraan elektriese potensiaal, wat dan weer versterk word deur membraan-gekoppelde H+-ATPase ensieme wat protone uit die sitoplasma uit pomp. Terwyl die gebruik van geneties-gemodifiseerde stamme net een fluksie-tot-ATP/ADP datapunt voorsien om met die wildetipe te vergelyk (wat nie voldoende is vir totale vraag-aanbod analise nie), het die behandeling van die wildetipe met ontkoppelaar meerdere datapunte voorsien waar fluksie en ATP/ADP waardes verskil volgens die konsentrasie van ontkoppelaar wat bygevoeg is. Die CS8 stam het ’n 19 % verminderde glukose fluskie getoon, asook ’n 23 % verminderde laktaat fluksie, in vergelyking met die wilde tipe MG1363. Die BK1506 stam het ’n 73 % toename in glukose fluskie getoon, asook ’n 34 % toename in laktaat fluksie, in vergelyking met die wilde tipe. Behandeling met 2 mM natrium asetaat het ’n 64 % toename in glukose fluksie veroorsaak, sowel as ’n 124 % toename in laktaat fluksie, en behandeling met 4 mM natrium asetaat het 108 % toename in glukose fluksie en 127 % toename in laktaat fluskie veroorsaak. Behandeling met verskillende konsentrasies natrium asetaat het genoeg data punte (fluksies met toepaslike ATP/ADP waardes) verskaf om die berekening van elastisiteits-koëffisiënt van die aanbod reaksie-blok tot veranderinge in ATP/ADP (εsupply ) te bereken. Die waardes was -5.6 vir glukose fluksie en -6.3 vir laktaat fluksie. ATP/ADP Die elastisiteits koëffisiënt was relatief hoog in vergelyking met waardes wat in soorteglyke studies op ander organismes bepaal is. Aangesien die fluksies van die aanbod en vraag reaksie blokke by ’n bestendige toestand dieselfde tempo het, kan die hoë waarde van die aanbod elastisiteits-koëffisiënt (wat die makliker een is om te meet) na die volgende afleidings lei: 1) meer kontrole mag in die ATP verbruikende reaksie-blok geleë wees (die elastisiteits-koëffisiënt is moeiliker om eksperimenteel te bepaal maar mag wel laer as die aanbod-elastisiteit wees), en 2) ATP/ADP homeostase word goed gehandhaaf, soos aangetoon deur die hoë aanbod-elastisiteit. Hierdie studie dien as ’n basis vir verdere vraag-aanbod analise in nie-groeiende L. lactis lot-kulture.

Lactic acid bacteria are essential as flavor producers of cheese and fermented products. They are capable of catabolizing aromatic, branched chain, and sulfur amino acids to flavor compounds. During cheese ripening the numbers of lactococcal colonies decrease, but lactococci survive without replication in culture. This prompted an investigation into possible mechanisms of catabolism of branched chain amino acids into branched chain fatty acids and the physiological relevance of amino acid catabolism to the bacteria. We hypothesized that lactococci catabolize branched chain amino acids to branched chain fatty acids during nonculturability. Lactococci, lactobacilli, and brevibacteria catabolized both branched chain amino acids and keto acids into branched chain fatty acids. Lactococci survived carbohydrate-limited conditions for over 4 yrs. Their survival was represented by maintaining intracellular ATP, enzyme activity, membrane integrity, capability of ATP- and PMF-dependent substrate transport, transcription, and catabolism of amino acids to fatty acids. Assays conducted with NMR spectroscopy coupled with in silico analysis showed that branched chain substrates are catabolized via keto acids, HMG-CoA, and acetyl-CoA to branched chain fatty acids. A short list of candidate genes was identified for the pathway by gene expression analysis coupled to NMR analysis. The expression of these genes and the presence of the related catabolites were identified in long-term starved cultures of nonculturable lactococci. This verified that catabolism of branched chain amino acids to branched chain fatty acids occurred during the nonculturable state only and in conditions of carbohydrate deprivation. The pathway also facilitated fixation of carbon by lactococci, revealing the mechanism of survival of lactococci over 4 yrs in culture without the addition of external carbon sources. Between strains the availability of carbohydrate and acid stress played significant roles in modulating their ability to produce branched chain catabolites. The ability of lactococci to catabolize branched chain amino acids during sugar starvation represents a shift in carbon catabolic routes. The identified pathway also represented a balance between catabolism and anabolism, suggesting that the bacteria were in a homeostatic state during nonculturability. We accepted the hypothesis that nonculturable lactococci catabolized branched chain amino acids to branched chain fatty acids during starvation./p>

Lactococci are widely used in the cheese industry as a starter culture. Starter cultures face carbohydrate starvation due to the absence of a fermentable carbohydrate in the cheese curd after pressing. Starvation leads to a decreased ability to synthesize ATP, generate a proton motive force, and accumulate nutrients necessary to maintain viability. The aim of this work was to investigate the culturability of lactococci grown with and without lactose in a chemically defined medium, and to define the metabolic changes that occur during carbohydrate starvation. Lactose metabolism provided energy for logarithmic phase growth and greater cell density in L. lactis ssp. lactis ML3 and L. lactis ssp. cremoris S2. However, the rate of lactose metabolism was strain dependent in that L. lactis ssp. lactis 11454 did not metabolize lactose as rapidly as did ML3 and S2. In the absence of lactose the cells became nonculturable on agar. In addition to becoming nonculturable, the aminopeptidase and lipase/ esterase activity became nonmeasurable after 21 d, and cellular metabolism was altered because of carbohydrate starvation. Nevertheless, the cells remained viable for up to 42 d in spent media as measured by fluorescent viability stains and intracellular ATP content. Fluorescent viability staining demonstrated that the cells maintained an intact cell membrane to contain their DNA, as well as to contain enzymes and ATP necessary to maintain viability and metabolic activity. With the addition of arginine to the basal medium, the survival time, cell number, and ATP concentration increased. Amino acids, including arginine, provided energy after carbohydrate exhaustion. At the onset of lactose exhaustion, the extracellular concentrations of arginine, glycine/valine, glutamate, and glutamine decreased in the media when energy was present for their transport. There was a significant increase in serine and methionine concentrations in the spent media over the same time period. These data indicated lactococci remained viable and metabolically active, but were nonculturable in response to carbohydrate starvation. Additionally, amino acids are in a dynamic state during carbohydrate starvation, and utilization of amino acids, such as arginine and serine, could facilitate lactococcal cells in maintaining viability in harsh environments such as ripening cheese.

Most pathogens gain access to their host through mucosal surfaces. It is therefore desirable to develop mucosal vaccines that elicit an immune response to prevent this crucial first step in infection. Current mucosal vaccines are live attenuated strains of pathogens. More recent efforts have focused on the use of recombinant non-pathogenic gram-positive bacteria as live vaccine delivery vectors. Here I have tested the potential of Lactococcus lactis to be used as a vaccine vector. A recombinant strain of L. lactis has been constructed which expresses and displays on its surface the C repeat region (CRR) of the M6 protein of Streptococcus pyogenes. I show that nasal vaccination of mice with this strain elicited strong salivary IgA and serum lgG response. These responses protected mice against a nasal challenge with S. pyogenes. Subcutaneous vaccination with the same strain of L. lactis produced a strong serum lgG response, but no salivary lgA response. Subcutaneous vaccination did not protect the mice against nasal infections when the mice were challenged with S. pyogenes. The immune response and protection afforded by concomitant vaccination by both nasal and subcutaneous routes were better that that seen in nasal vaccination alone. This study shows that an effective vaccine against S. pyogenes is possible using L. lactis as a vaccine vector. It also opens up the potential of L. lactis to be used in the development of vaccines to other mucosal infections. / Graduation date: 2004

Graduation date: 1993

Les résultats obtenus dans ce travail ont permis de démontrer que chez les deux bactéries lactiques modèles, L. lactis subsp. cremoris et O. oeni, la transcription du gène cfa, codant pour la Cfa synthase, est stimulée lorsque les cellules entrent en phase stationnaire de croissance ou lorque que les cellules sont cultivées en conditions de stress (milieu acide ou présence d'éthanol dans le milieu). Le rôle des CFA a pû être appréhendé par l'analyse physiologique comparative de la souche parentale L. lactis subsp. cremoris et du mutant Δcfa généré chez cette souche. Les forts pourcentages de survie obtenus chez les souches cultivées à pH 5,0, puis subissant un stress acide (pH 3,0), prouvent que la cyclopropanation des acides gras insaturés n'est pas indispensable à la survie de L. lactis subsp. cremoris en conditions de stress acide. En outre, les données d'anisotropie de fluorescence démontrent que la présence de CFAs membranaires ne permet pas de réguler le niveau de fluidité membranaire, en particulier avec les souches cultivées en présence d'éthanol, où une fluidification membranaire est observée dans tous les cas. L'hypothèse d'un équilibre entre les acides palmitoléique / cis-vaccénique / lactobacillique pour réguler la fluidité membranaire chez L. lactis subsp. cremoris est avancée. L'étude du rôle physiologique des CFA chez O. oeni nécessite l'expression du gène cfa de la bactérie en système hétérologue. Les résultats obtenus confirment la fonctionnalité du gène chez la bactérie hôte L. lactis subsp. cremoris, cependant la cyclisation du précurseur acide cis-vaccénique, reste partielle chez la souche mutante complémentée. Un travail de caractérisation biochimique in vitro de l'enzyme Cfa synthase de O. oeni a donc été entrepris afin d'expliquer la faible efficacité de l'enzyme de O. oeni chez la bactérie hôte. Les travaux réalisés ont permis la surproduction et la purification de l'enzyme. Une technique de mesure d'activité in vitro a été également développée. Une stratégie d'expression du gène cfa de O. oeni en système hétérologue dans la bactérie hôte E. coli BL21 Star a permis la surpoduction d'une protéine d'environ 45 kDa, en accord avec la masse moléculaire théorique de la Cfa synthase de O. oeni. A partir de l'extrait protéique, une purification a été réalisée par chromatographie d'affinité sur colonne d'agarose nickel. Les tests d'activité enzymatique in vitro ont pu été réalisés. La température optimale de l'enzyme est de 35,8°C. Son pH optimal est de 5,6. Même en se plaçant dans les conditions physico-chimiques optimales de l'enzyme, nous constatons que la cyclisation in vitro de l'acide cis-vaccénique issu des phospholipides membranaires du mutant L. lactis subsp. cremoris Δcfa reste partielle. Ceci induit une détermination expérimentale de valeurs de KM et Vmax largement supérieures aux données citées dans la littérature. La différence, entre les deux bactéries modèles, de nature et de répartition des phospholipides membranaires pourrait expliquer l'action partielle de la Cfa synthase de O. oeni.